FDA Gives uniQure’s Huntington’s Therapy Priority Review
The FDA accepted uniQure’s application for review and set a May 1, 2027 target date for action on the gene therapy.
Makkler Newsroom · Nov 2, 03:27 PM · 1 min read
Market closed· · USD · Data may be delayed
Avg. target $59.33 (+171.2%)
Prices may be delayed and are for informational purposes only - not investment advice.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.